Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity
- PMID: 31179659
- PMCID: PMC6557791
- DOI: 10.3341/kjo.2019.0011
Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity
Abstract
Purpose: To compare long-term refractive outcomes associated with intravitreal anti-vascular endothelial growth factor (VEGF) versus laser photocoagulation treatment for retinopathy of prematurity (ROP).
Methods: A total of 52 eyes from 27 ROP patients treated at two tertiary referral-based hospitals from August 2006 to December 2013 were reviewed. The primary outcome was refractive error measured at the age of 4 years, accounting for within-patient inter-eye correlation. Secondary outcomes included the recurrence rate and treatment complications.
Results: The mean age at refraction was 4.7 ± 0.3 years in the laser group (n = 30) and 4.4 ± 0.3 years in the anti-VEGF group (n = 22). No significant differences were noted in gestational age, birthweight, post-menstrual age at treatment, or ROP stage/zone distribution between groups. Mean spherical equivalent was also not significantly different (-1.0 diopters in the laser group and -0.3 diopters in the injection group, p = 0.603). Clustered regression analysis revealed that only gestational age was significantly correlated with mean spherical equivalent (p < 0.001; 95% confidence interval, -0.007 to -0.002). Recurrence was noted in four eyes (13.3%) in the laser group, but this difference was not significant (p = 0.128). There were no major systemic complications reported in either group.
Conclusions: Treatment type, whether laser or anti-VEGF injection, does not appear to influence long-term refractive outcomes in ROP. Concern regarding refractive outcomes should not be the most important factor when selecting ROP treatment modality.
Keywords: Intravitreal injections; Laser therapy; Refractive errors; Retinopathy of prematurity; Vascular endothelial growth factor A.
© 2019 The Korean Ophthalmological Society.
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Figures

Similar articles
-
Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.PLoS One. 2019 Dec 2;14(12):e0225643. doi: 10.1371/journal.pone.0225643. eCollection 2019. PLoS One. 2019. PMID: 31790445 Free PMC article.
-
Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.Curr Eye Res. 2017 Jul;42(7):1054-1058. doi: 10.1080/02713683.2016.1264607. Epub 2017 Jan 27. Curr Eye Res. 2017. PMID: 28128986
-
Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.Curr Eye Res. 2017 Mar;42(3):462-469. doi: 10.1080/02713683.2016.1196709. Epub 2016 Jul 15. Curr Eye Res. 2017. PMID: 27420302
-
Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.Surv Ophthalmol. 2024 Jul-Aug;69(4):585-605. doi: 10.1016/j.survophthal.2024.02.005. Epub 2024 Mar 1. Surv Ophthalmol. 2024. PMID: 38432359
-
Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.Ophthalmologica. 2015;234(4):211-7. doi: 10.1159/000439182. Epub 2015 Sep 23. Ophthalmologica. 2015. PMID: 26393895
Cited by
-
Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.PLoS One. 2019 Dec 2;14(12):e0225643. doi: 10.1371/journal.pone.0225643. eCollection 2019. PLoS One. 2019. PMID: 31790445 Free PMC article.
-
Oxygen care and treatment of retinopathy of prematurity in ocular and neurological prognosis.Sci Rep. 2022 Jan 10;12(1):341. doi: 10.1038/s41598-021-04221-8. Sci Rep. 2022. PMID: 35013470 Free PMC article.
-
A comparative study of stereopsis in term and preterm children with and without retinopathy of prematurity.Graefes Arch Clin Exp Ophthalmol. 2024 Aug;262(8):2685-2694. doi: 10.1007/s00417-024-06402-3. Epub 2024 Mar 20. Graefes Arch Clin Exp Ophthalmol. 2024. PMID: 38507045
-
Evaluation of retinal vascularization in retinopathy of prematurity regressed after intravitreal ranibizumab monotherapy or without treatment based on fluorescein angiography.Sci Rep. 2023 Nov 15;13(1):19946. doi: 10.1038/s41598-023-47212-7. Sci Rep. 2023. PMID: 37968276 Free PMC article.
-
Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.Int Ophthalmol. 2023 Mar;43(3):1027-1062. doi: 10.1007/s10792-022-02480-6. Epub 2022 Oct 10. Int Ophthalmol. 2023. PMID: 36214992 Free PMC article.
References
-
- Kushner BJ, Essner D, Cohen IJ, Flynn JT. Retrolental fibroplasia. II. Pathologic correlation. Arch Ophthalmol. 1977;95:29–38. - PubMed
-
- Darlow BA. Retinopathy of prematurity: new developments bring concern and hope. J Paediatr Child Health. 2015;51:765–770. - PubMed
-
- Hoogerwerf A, Schalij-Delfos NE, van Schooneveld MJ, Termote JU. Incidence of retinopathy of prematurity over the last decade in the Central Netherlands. Neonatology. 2010;98:137–142. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources